Nine -valent HPV vaccine expansion!How long will "difficulty find"?

On the evening of August 30, Murisha Dong quietly released heavy news.

Merhado Chinese official micro -issued text says that the new indication of the nine -valent nine -valent papilloma virus vaccine (brewing yeast) (hereinafter referred to as the "nine -valent HPV vaccine") has been approved by the National Drug Administration of China, and the Merhado nine -valent HPV vaccine The applicable population is extended to women 9 to 45 years old.

This expansion will undoubtedly expand the market for the nine -valent HPV vaccine.

At present, the HPV vaccine, which has been approved by my country, includes imported Merosa East Four Valentine Vaccine "Jiada Xiu", Nine -Valental Valles "Jiada Xiu 9"; Grandulosk's two -valent vaccine "Herry"; and domestic 10,000 Thai creature's binary vaccine "Xin Kening" and the binary vaccine of Watson Biological "Wozawa". At present, the nine -valent HPV vaccine is the highest -priced vaccine that can be used to protect HPV viruses on the market. It is also the most sought after vaccine.

Earlier, only two -valent HPV vaccine was approved for women aged 9 to 45, and the quadrilateral HPV vaccine was 20 to 45 years old. The expansion of the nine -valent vaccine will obviously affect the market of the two vaccines above.

"One needle and one medicine" in the Chinese market

Meridon is a global vaccine giant. In June 2006, its four -valent HPV vaccine was approved by the US Food and Drug Administration to be listed, becoming the first HPV vaccine to be listed worldwide. In December 2014, the company was listed on a wider range of nine -valent HPV vaccines.

China has now become a vital part of Merck's global growth strategy. Merck China headquarters is located in Shanghai. At the same time, there is a R & D center in Beijing and a factory in Hangzhou, which has achieved three engines of research and development, manufacturing and business operations.

Meridodon mainly relies on "one needle and one medicine" in the Chinese market, namely HPV vaccine and K -drugs (one of Keytruda). K-medicine insists that he does not enter the medical insurance. At the same time, he has been "impact" by various PD-1 in turns, but relying on many adaptives and unique curative effects, unique and unique, maintaining high sales. In the first half of 2022, K medicine became a non -new crown drug with a "only two" sales in the world.

Merhadon's quadrilateral HPV vaccine and nine -valent HPV vaccine obtained the drug registration approval issued by the State Food and Drug Administration in 2017 and 2018. Zhifei Biological is its exclusive agent in China.

The latest disclosure of Zhifei Bio's latest 2022 report shows that during the reporting period, the company's quadrimal HPV vaccine approved volume was 4.8767 million, a year -on -year increase of 60.10%; Essence

Meridon also disclosed in its half -year report in the 2022nd report that in the first six months of this year, China's sales increased by 87%year -on -year to $ 2.57 billion. Meridon specifically pointed out that in recent quarters, the demand for Jiadaxiu in the Chinese market has continued to be high, and it has continuously promoted the company's Chinese business expansion.

How long will "one seedlings find it"?

The Nine -valent HPV vaccine has always been in short supply since its domestic listing in April 2018. "One seedlings" have even spawned the rampant "ox", as well as professional technology and business teams, business involves grabbing, existing seedlings, and smuggling Hong Kong seedlings. There are scalpel bluntly tens of thousands of monthly income.

Since the beginning of this year, the HPV vaccine industry has been controversial. In April, the WHO's immunization strategy experts formed a HPV vaccine to take over one dose. This has made most HPV vaccine companies claim that the two pins and three -pin products have generated a lot of controversy. In May, the approval of the second -valent HPV vaccine for two doses of the two -valent HPV vaccine also exacerbated the change of market supply and vaccination immunization procedures. Essence

Behind the long -term "unable to fight" and "unable to afford" HPV vaccine, it directly points to the domestic limited vaccine supply. But domestic vaccine vendors are catching up.

In May 2020, the HPV binary vaccine of Wantai Bio was officially put into the market and started to sell. In March of this year, Watson Biological's binary HPV vaccine was also approved for listing. Immediately after, the nine -valent HPVs of Kangle Guardian, Ruico Biology, and Boyi Bio and other companies have entered the phase III clinical; the two -price, four -valent, and even fourteen -valent product research and development of other companies are also hot.

Not only that, in addition to the Chinese market, domestic HPV vaccine companies are also eager to try the global market. After passing the pre -certification (PQ certification) of the WHO, Wantai Bio is registered in Morocco, Thailand, Indonesia, Malaysia and other countries. It was previously reached an agreement with Russian Pharmaceuticals with Russian Pharmaceuticals. Agree in Russia.

"Golden Two" on the vaccine line

Merhadon also "can't sit still."

On April 4 this year, Meridodon announced a large investment in production. Recently, the vaccine production facility located in Erkton, Virginia, USA. Under the review and approval of the regulatory authorities, the construction area was 120,000 square feet, and the new increase was 150 newly increased by 150 The job job further enhances the company's HPV vaccine production and supply capacity.

In 2019, Merck also invested more than 1 billion US dollars to expand existing production facilities and build new facilities to meet the global huge demand for HPV vaccines.

The reporter noticed that last year, Meridon also launched a large -scale 3 -phase clinical trial in China in China to evaluate the protection, immunogenicity and safety of the nine -valent papilloma virus (HPV) vaccine in men Essence Earlier, HPV vaccines have been proposed by US FDA and other institutions to expand for men. At present, my country's HPV vaccination has not been included in the national immunization plan, and is vaccinated in accordance with the principles of voluntary at their own expense. The National Health and Health Commission actively promotes the place where conditions permitted the HPV vaccination into the local policy of benefiting the people. The provinces of Guangdong, Hainan, and Fujian have successively launched the province's free vaccination of domestic binary HPV vaccines for free to take over the province, and incorporated the provincial party committee and provincial government for private projects in 2022.

The National Health and Health Commission recently stated that it will vigorously promote the experience of Guangdong, Hainan, Fujian and other provinces, summarize the experience and practices of various channels such as government livelihood projects and medical insurance funds in various places, encourage localities to try first, and focus on promoting regions with mature conditions to introduce the first introduction Free HPV vaccination policies and continuously increase the HPV vaccination rate of girls with a suitable age.

The market is large enough and competition is fierce enough.

Tian Anna, a senior vice president of Global Global and President of Merhado, said that the expansion of the applied age of the nine -valent HPV vaccine shows that the Chinese government's determination to accelerate the elimination of cervical cancer. Hyd sex.

In the future of the HPV vaccine market, "a single show" may be difficult to see, "Who will get greater market share" suspense is getting bigger and bigger, but it is certain that more and more Chinese women can get Protect.

- END -